Insider Buying: Opko Health, Inc. (OPK) CEO Buys $23,688.00 in Stock

Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 3,600 shares of the firm’s stock in a transaction that occurred on Friday, June 30th. The shares were acquired at an average price of $6.58 per share, with a total value of $23,688.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $20,193,697.58. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, July 27th, Phillip Md Et Al Frost acquired 23,600 shares of Opko Health stock. The stock was purchased at an average price of $6.34 per share, with a total value of $149,624.00.
  • On Wednesday, July 26th, Phillip Md Et Al Frost acquired 36,200 shares of Opko Health stock. The stock was purchased at an average price of $6.39 per share, with a total value of $231,318.00.
  • On Tuesday, July 25th, Phillip Md Et Al Frost purchased 39,800 shares of Opko Health stock. The shares were bought at an average price of $6.41 per share, with a total value of $255,118.00.
  • On Monday, July 24th, Phillip Md Et Al Frost purchased 45,000 shares of Opko Health stock. The shares were bought at an average price of $6.42 per share, with a total value of $288,900.00.
  • On Thursday, July 20th, Phillip Md Et Al Frost purchased 5,400 shares of Opko Health stock. The shares were bought at an average price of $6.46 per share, with a total value of $34,884.00.
  • On Monday, July 17th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The shares were bought at an average price of $6.04 per share, with a total value of $10,872.00.
  • On Friday, July 14th, Phillip Md Et Al Frost purchased 12,600 shares of Opko Health stock. The shares were bought at an average price of $6.16 per share, with a total value of $77,616.00.
  • On Wednesday, July 12th, Phillip Md Et Al Frost purchased 3,600 shares of Opko Health stock. The shares were bought at an average price of $6.12 per share, with a total value of $22,032.00.
  • On Monday, July 10th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were bought at an average price of $6.19 per share, with a total value of $309,500.00.
  • On Thursday, July 6th, Phillip Md Et Al Frost purchased 25,000 shares of Opko Health stock. The shares were bought at an average price of $6.29 per share, with a total value of $157,250.00.

Opko Health, Inc. (OPK) traded down 0.16% during mid-day trading on Friday, hitting $6.31. The company had a trading volume of 2,956,712 shares. The company’s market cap is $3.53 billion. The company’s 50 day moving average price is $6.48 and its 200-day moving average price is $7.46. Opko Health, Inc. has a one year low of $5.99 and a one year high of $12.15.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.02. The company had revenue of $296.10 million during the quarter, compared to analyst estimates of $313.36 million. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. The business’s revenue for the quarter was up 1.8% compared to the same quarter last year. During the same period last year, the company earned ($0.02) EPS. Equities research analysts anticipate that Opko Health, Inc. will post ($0.20) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Insider Buying: Opko Health, Inc. (OPK) CEO Buys $23,688.00 in Stock” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/07/30/phillip-md-et-al-frost-buys-3600-shares-of-opko-health-inc-opk-stock-updated-updated-updated.html.

A number of brokerages recently weighed in on OPK. Jefferies Group LLC reaffirmed a “hold” rating and set a $8.00 price objective on shares of Opko Health in a report on Monday, June 12th. Zacks Investment Research raised Opko Health from a “hold” rating to a “buy” rating and set a $7.25 price objective on the stock in a report on Friday, July 21st. Barrington Research upped their price objective on Opko Health to $11.00 and gave the stock an “outperform” rating in a report on Tuesday, July 18th. BidaskClub raised Opko Health from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $19.50 target price on shares of Opko Health in a report on Tuesday, June 6th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Opko Health has an average rating of “Buy” and a consensus price target of $14.72.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Financial Architects Inc increased its position in Opko Health by 45.0% in the second quarter. Financial Architects Inc now owns 15,460 shares of the biotechnology company’s stock worth $102,000 after buying an additional 4,800 shares during the period. AQR Capital Management LLC purchased a new stake in Opko Health during the fourth quarter worth approximately $105,000. Timber Hill LLC purchased a new stake in Opko Health during the first quarter worth approximately $114,000. Comerica Bank purchased a new stake in Opko Health during the fourth quarter worth approximately $117,000. Finally, World Asset Management Inc boosted its position in Opko Health by 23.6% in the first quarter. World Asset Management Inc now owns 15,176 shares of the biotechnology company’s stock worth $121,000 after buying an additional 2,900 shares during the period. 23.64% of the stock is currently owned by institutional investors.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply